Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients

Exclusion Criteria

• •Patients also with non-allergic rhinitis with different causes.
• •Patients with severe asthma who meet the followings.
• •Presence of nasal polyps or any clinically important nasal anomaly.
• •History of acute • chronic sinusitis within 30 days of Visit 1
• •History of intranasal / eye surgeries within 3 months of Visit 1
• •Initiation of immunotherapy or dose modification within 1 month prior to Visit 1
• •Upper respiratory infections including cold and systemic infections within 3 weeks of Visit 1.
• •Chronic use of tricyclic antidepressants, beta agonists, bronchodilators, etc. that may affect the efficacy of study drug
• •At Visit 2, patients who recorded Daytime Nasal Symptom Scores for fewer than 4 days in the subject diary during the last one week of baseline period